UnitedHealth Follows Competitors, Replaces Humira With Lower-Cost Biosimilars
UnitedHealth Follows Competitors, Replaces Humira With Lower-Cost Biosimilars
Reuters highlights that UnitedHealth Group Inc. (NYSE:UNH) reportedly announced on Tuesday that it will remove AbbVie Inc.'s (NYSE:ABBV) blockbuster drug Humira from some of its preferred reimbursement lists starting January 1, 2025. The company will recommend lower-cost biosimilar versions instead.
据报道，UnitedHealth Group Inc.（纽约证券交易所代码：UNH）周二宣布，它将撤出艾伯维公司。”s（纽约证券交易所代码：ABBV）的重磅药物Humira将从2025年1月1日起从其部分首选报销清单中列出。该公司将改为推荐成本较低的生物仿制药版本。
This move is part of a larger trend in the U.S. pharmaceutical market, as health plans seek to cut costs by promoting alternatives to high-priced drugs.
此举是美国药品市场更大趋势的一部分，因为健康计划试图通过推广高价药物的替代品来削减成本。
Also Read: FTC Investigation Uncovers Anti-Competitive Practices By Handful Of Pharmacy Benefit Managers, Including CVS Health, UnitedHealth.
另请阅读：联邦贸易委员会的调查发现了包括CVS Health、UnitedHealth在内的少数药房福利经理的反竞争行为。
Reuters highlights that Amgen Inc's (NASDAQ:AMGN) Amjevita, managed by its pharmacy benefits unit, Optum Rx, is among the biosimilars covered under UnitedHealth's lists for commercial health plans.
路透社强调，由其药房福利部门Optum Rx管理的安进公司（纳斯达克股票代码：AMGN）的Amjevita是UnitedHealth商业健康计划清单所涵盖的生物仿制药之一。
With this decision, Optum becomes the last of the three largest U.S. pharmacy benefit managers (PBMs) to exclude Humira.
通过这一决定，Optum成为美国三大药房福利管理公司（PBM）中最后一家将Humira排除在外的公司。
Cigna Corporation (NYSE:CI) announced last month that it would remove Humira from some of its lists in 2025, following a similar decision by CVS Health Inc's (NYSE:CVS) Caremark unit in April.
信诺公司（纽约证券交易所代码：CI）上个月宣布，将在2025年将Humira从部分名单中删除，此前CVS Health Inc（纽约证券交易所代码：CVS）的Caremark部门在4月做出了类似的决定。
CVS's action led to a swift shift, with more patients transitioning to Sandoz Group AG's (OTC:SDZNY) (OTC:SDZXF) biosimilar version of Humira in just three weeks than in the previous 15 months combined.
CVS的行动导致了迅速的转变，在短短三周内过渡到山德士集团股份公司（场外交易代码：SDZNY）（场外交易代码：SDZXF）生物仿制药版本的Humira的患者比前15个月的总和还要多。
Cigna plans to cover biosimilars like Boehringer Ingelheim's Cyltezo, Simlandi from Teva Pharmaceutical Industries Ltd (NYSE:TEVA), and Alvotech's (NASDAQ:ALVO) products, including an unbranded version of Sandoz's Hyrimoz, as replacements for Humira.
信诺计划涵盖勃林格英格海姆的Cyltezo、梯瓦制药工业有限公司（纽约证券交易所代码：TEVA）的西姆兰迪和Alvotech（纳斯达克股票代码：ALVO）的生物仿制药，包括山德士的Hyrimoz的无品牌版本，作为Humira的替代品。
UnitedHealth noted that patients would still have access to Humira until the FDA designates the preferred biosimilars as interchangeable with the original drug, per the report. The FDA is expected to make this designation in 2025.
报告称，UnitedHealth指出，在美国食品药品管理局将首选生物仿制药指定为可与原始药物互换之前，患者仍然可以获得Humira。美国食品和药物管理局预计将在2025年作出这一指定。
Despite the growing competition, AbbVie has managed to retain a dominant share of the U.S. Humira market throughout 2023. This has been achieved through favorable negotiations with PBMs, even as biosimilar alternatives from companies like Pfizer Inc (NYSE:PFE) entered the market.
尽管竞争日益激烈，但艾伯维在整个2023年仍设法保持了美国Humira市场的主导份额。尽管辉瑞公司（纽约证券交易所代码：PFE）等公司的生物仿制药替代品已进入市场，但这是通过与PBM的有利谈判实现的。
As per a Reuters report, Humira has still managed to retain over 80% of its patients even after facing lower-priced rivals in the U.S. over the past year.
根据路透社的报道，尽管在过去的一年中在美国面临价格较低的竞争对手，Humira仍设法留住了80％以上的患者。
Following their launch last year, pharmacy benefit managers largely influenced patient access, with minimal incentive for doctors to switch to these alternatives.
自去年推出以来，药房福利管理机构在很大程度上影响了患者的可及性，而医生转向这些替代方案的动机微乎其微。
In May, Cantor Fitzgerald said AbbVie had positioned itself to absorb Humira biosimilar erosion and achieve modest operational revenue growth.
坎托·菲茨杰拉德在5月表示，艾伯维已做好吸收Humira生物仿制药侵蚀的准备，实现适度的运营收入增长。
Price Action: UNH stock is down 2% at $587.07 at last check Wednesday.
价格走势：周三最后一次检查时，UNH股价下跌2％，至587.07美元。
Photo via Shutterstock
照片来自 Shutterstock
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免责声明：此内容部分是在人工智能工具的帮助下制作的，并由Benzinga的编辑审阅和发布。
- GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech.
- 葛兰素史克停止单纯疱疹病毒疫苗的开发，为Moderna、BioNTech等其他竞争者扫清了道路。
